|
市場調査レポート
商品コード
1530899
HIV治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024～2034年予測HIV Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034 |
||||||
カスタマイズ可能
|
|||||||
価格
| HIV治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024～2034年予測 |
|
出版日: 2024年06月19日
発行: Transparency Market Research
ページ情報: 英文 153 Pages
納期: 2～10営業日
|
- 全表示
- 概要
- 図表
- 目次
概要
HIV治療薬市場-調査範囲
TMRの調査レポート「HIV治療薬の世界市場」は、2024～2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018～2034年までの世界のHIV治療薬市場の収益と予測を提供しています。また、2024～2034年までの世界のHIV治療薬市場の複合年間成長率（CAGR %）も掲載しています。
本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、HIV治療薬市場を推察しました。
| 市場スナップショット | |
|---|---|
| 2023年の市場規模 | 286億米ドル |
| 2034年の市場規模 | 475億米ドル |
| CAGR | 4.7% |
当レポートでは、世界のHIV治療薬市場の競合情勢について調査しています。世界のHIV治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界のHIV治療薬市場における参入企業の属性です。
目次
第1章 序文
第2章 前提条件と調査手法
第3章 エグゼクティブサマリー：世界市場
第4章 市場概要
- イントロダクション
- 概要
- 市場力学
- 世界の市場分析と予測、2020～2034年
第5章 主要洞察
- パイプライン分析
- 主要製品/ブランド分析
- 主要M&A
- COVID-19による産業への影響
第6章 世界の市場分析と予測：薬剤タイプ別
- イントロダクションと定義
- 主要調査結果・発展
- 市場金額予測：薬剤タイプ別、2020～2034年
- ヌクレオシド逆転写酵素阻害剤（NRTI）
- 非ヌクレオシド系逆転写酵素阻害剤（NNRTI）
- プロテアーゼ阻害剤（PI）
- 融合阻害剤（FI）
- C-Cケモカイン受容体5型（CCR5）
- インテグラーゼ阻害剤
- 付着阻害物質
- 付着後阻害剤
- 薬剤動態増強剤
- 曝露後予防（PEP）
- 曝露前予防（PrEP）
- その他（HIV治療薬併用など）
- 市場の魅力分析：薬剤タイプ別
第7章 世界の市場分析と予測：流通チャネル別
- イントロダクションと定義
- 主要調査結果・発展
- 市場金額予測：流通チャネル別、2020～2034年
- 病院薬局
- 小売薬局
- オンライン薬局
- 市場の魅力分析：流通チャネル別
第8章 世界の市場分析と予測：地域別
- 主要調査結果
- 市場金額予測：地域別、2020～2034年
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
- 市場の魅力分析：地域別
第9章 北米の市場分析と予測
第10章 欧州の市場分析と予測
第11章 アジア太平洋の市場分析と予測
第12章 ラテンアメリカ市場分析と予測
第13章 中東・アフリカの市場分析と予測
第14章 競合情勢
- 市場企業-競争マトリックス（企業階層と規模別）
- 市場シェア分析：企業別（2023年）
- 企業プロファイル
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GSK plc
- AbbVie Inc.
- Cipla Limited
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
図表
List of Tables
- Table 01: Global HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 02: Global HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
- Table 03: Global HIV Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
- Table 04: North America HIV Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
- Table 05: North America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 06: North America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
- Table 07: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
- Table 08: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 09: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
- Table 10: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
- Table 11: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 12: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
- Table 13: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
- Table 14: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 15: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
- Table 16: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
- Table 17: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
- Table 18: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
- Figure 01: Global HIV Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
- Figure 02: Global HIV Drugs Market Revenue (US$ Bn), by Drug Type, 2023
- Figure 03: Global HIV Drugs Market Value Share, by Drug Type, 2023
- Figure 04: Global HIV Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
- Figure 05: Global HIV Drugs Market Value Share, by Distribution Channel, 2023
- Figure 06: Global HIV Drugs Market Value Share, by Region, 2023
- Figure 07: Global HIV Drugs Market Value (US$ Bn) Forecast, 2020-2034
- Figure 08: Global HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 09: Global HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 10: Global HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 11: Global HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
- Figure 12: Global HIV Drugs Market Value Share Analysis, by Region, 2023 and 2034
- Figure 13: Global HIV Drugs Market Attractiveness Analysis, by Region, 2020-2034
- Figure 14: North America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
- Figure 15: North America HIV Drugs Market Attractiveness Analysis, by Country, 2020-2034
- Figure 16: North America HIV Drugs Market Value Share Analysis, by Country, 2023 and 2034
- Figure 17: North America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 18: North America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 19: North America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 20: North America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
- Figure 21: Europe HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
- Figure 22: Europe HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
- Figure 23: Europe HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
- Figure 24: Europe HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 25: Europe HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 26: Europe HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 27: Europe HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
- Figure 28: Asia Pacific HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
- Figure 29: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
- Figure 30: Asia Pacific HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
- Figure 31: Asia Pacific HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 32: Asia Pacific HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 33: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 34: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
- Figure 35: Latin America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
- Figure 36: Latin America HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
- Figure 37: Latin America HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
- Figure 38: Latin America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 39: Latin America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 40: Latin America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 41: Latin America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
- Figure 42: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
- Figure 43: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
- Figure 44: Middle East & Africa HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
- Figure 45: Middle East & Africa HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
- Figure 46: Middle East & Africa HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
- Figure 47: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
- Figure 48: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
目次
Product Code: TMRGL86226
HIV Drugs Market - Scope of Report
TMR's report on the global HIV drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global HIV drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HIV drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HIV drugs market.
| Market Snapshot | |
|---|---|
| Market Value in 2023 | US$ 28.6 Bn |
| Market Value in 2034 | US$ 47.5 Bn |
| CAGR | 4.7% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HIV drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HIV drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HIV drugs market.
The report delves into the competitive landscape of the global HIV drugs market. Key players operating in the global HIV drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HIV drugs market profiled in this report.
Key Questions Answered in Global HIV drugs Market Report:
- What is the sales/revenue generated by HIV drugs across all regions during the forecast period?
- What are the opportunities in the global HIV drugs market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
HIV Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global HIV drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global HIV drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HIV drugs market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global HIV Drugs Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global HIV Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global HIV Drugs Market Analysis and Forecast, by Drug Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Drug Type, 2020-2034
- 6.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 6.3.3. Protease Inhibitors (PIs)
- 6.3.4. Fusion Inhibitors (FIs)
- 6.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 6.3.6. Integrase Inhibitors
- 6.3.7. Attachment Inhibitors
- 6.3.8. Post Attachment Inhibitors
- 6.3.9. Pharmacokinetic Enhancers
- 6.3.10. Post-Exposure Prophylaxis (PEP)
- 6.3.11. Pre-Exposure Prophylaxis (PrEP)
- 6.3.12. Others (Combination HIV Medications, etc.)
- 6.4. Market Attractiveness Analysis, by Drug Type
7. Global HIV Drugs Market Analysis and Forecast, by Distribution Channel
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global HIV Drugs Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region, 2020-2034
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America HIV Drugs Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Key Findings
- 9.3. Market Value Forecast, by Drug Type, 2020-2034
- 9.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 9.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 9.3.3. Protease Inhibitors (PIs)
- 9.3.4. Fusion Inhibitors (FIs)
- 9.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 9.3.6. Integrase Inhibitors
- 9.3.7. Attachment Inhibitors
- 9.3.8. Post Attachment Inhibitors
- 9.3.9. Pharmacokinetic Enhancers
- 9.3.10. Post-Exposure Prophylaxis (PEP)
- 9.3.11. Pre-Exposure Prophylaxis (PrEP)
- 9.3.12. Others (Combination HIV Medications, etc.)
- 9.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Value Forecast, by Country, 2020-2034
- 9.5.1. U.S.
- 9.5.2. Canada
- 9.6. Market Attractiveness Analysis
- 9.6.1. By Drug Type
- 9.6.2. By Distribution Channel
- 9.6.3. By Country
10. Europe HIV Drugs Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Drug Type, 2020-2034
- 10.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 10.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 10.3.3. Protease Inhibitors (PIs)
- 10.3.4. Fusion Inhibitors (FIs)
- 10.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 10.3.6. Integrase Inhibitors
- 10.3.7. Attachment Inhibitors
- 10.3.8. Post Attachment Inhibitors
- 10.3.9. Pharmacokinetic Enhancers
- 10.3.10. Post-Exposure Prophylaxis (PEP)
- 10.3.11. Pre-Exposure Prophylaxis (PrEP)
- 10.3.12. Others (Combination HIV Medications, etc.)
- 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Italy
- 10.5.5. Spain
- 10.5.6. Rest of Europe
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Type
- 10.6.2. By Distribution Channel
- 10.6.3. By Country/Sub-region
11. Asia Pacific HIV Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Drug Type, 2020-2034
- 11.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 11.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 11.3.3. Protease Inhibitors (PIs)
- 11.3.4. Fusion Inhibitors (FIs)
- 11.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 11.3.6. Integrase Inhibitors
- 11.3.7. Attachment Inhibitors
- 11.3.8. Post Attachment Inhibitors
- 11.3.9. Pharmacokinetic Enhancers
- 11.3.10. Post-Exposure Prophylaxis (PEP)
- 11.3.11. Pre-Exposure Prophylaxis (PrEP)
- 11.3.12. Others (Combination HIV Medications, etc.)
- 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Online Pharmacies
- 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Type
- 11.6.2. By Distribution Channel
- 11.6.3. By Country/Sub-region
12. Latin America HIV Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Drug Type, 2020-2034
- 12.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 12.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 12.3.3. Protease Inhibitors (PIs)
- 12.3.4. Fusion Inhibitors (FIs)
- 12.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 12.3.6. Integrase Inhibitors
- 12.3.7. Attachment Inhibitors
- 12.3.8. Post Attachment Inhibitors
- 12.3.9. Pharmacokinetic Enhancers
- 12.3.10. Post-Exposure Prophylaxis (PEP)
- 12.3.11. Pre-Exposure Prophylaxis (PrEP)
- 12.3.12. Others (Combination HIV Medications, etc.)
- 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Online Pharmacies
- 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Type
- 12.6.2. By Distribution Channel
- 12.6.3. By Country/Sub-region
13. Middle East & Africa HIV Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Drug Type, 2020-2034
- 13.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 13.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 13.3.3. Protease Inhibitors (PIs)
- 13.3.4. Fusion Inhibitors (FIs)
- 13.3.5. C-C Chemokine Receptor Type 5 (CCR5)
- 13.3.6. Integrase Inhibitors
- 13.3.7. Attachment Inhibitors
- 13.3.8. Post Attachment Inhibitors
- 13.3.9. Pharmacokinetic Enhancers
- 13.3.10. Post-Exposure Prophylaxis (PEP)
- 13.3.11. Pre-Exposure Prophylaxis (PrEP)
- 13.3.12. Others (Combination HIV Medications, etc.)
- 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Online Pharmacies
- 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Type
- 13.6.2. By Distribution Channel
- 13.6.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 14.2. Market Share Analysis, by Company (2023)
- 14.3. Company Profiles
- 14.3.1. Teva Pharmaceutical Industries Ltd.
- 14.3.1.1. Company Overview
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Financial Overview
- 14.3.1.5. Strategic Overview
- 14.3.2. Boehringer Ingelheim International GmbH
- 14.3.2.1. Company Overview
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Financial Overview
- 14.3.2.5. Strategic Overview
- 14.3.3. Johnson & Johnson
- 14.3.3.1. Company Overview
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Financial Overview
- 14.3.3.5. Strategic Overview
- 14.3.4. F. Hoffmann-La Roche Ltd.
- 14.3.4.1. Company Overview
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Financial Overview
- 14.3.4.5. Strategic Overview
- 14.3.5. Gilead Sciences, Inc.
- 14.3.5.1. Company Overview
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Financial Overview
- 14.3.5.5. Strategic Overview
- 14.3.6. GSK plc
- 14.3.6.1. Company Overview
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Financial Overview
- 14.3.6.5. Strategic Overview
- 14.3.7. AbbVie Inc.
- 14.3.7.1. Company Overview
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Financial Overview
- 14.3.7.5. Strategic Overview
- 14.3.8. Cipla Limited
- 14.3.8.1. Company Overview
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Financial Overview
- 14.3.8.5. Strategic Overview
- 14.3.9. Bristol-Myers Squibb Company
- 14.3.9.1. Company Overview
- 14.3.9.2. Product Portfolio
- 14.3.9.3. SWOT Analysis
- 14.3.9.4. Financial Overview
- 14.3.9.5. Strategic Overview
- 14.3.10. Merck & Co., Inc.
- 14.3.10.1. Company Overview
- 14.3.10.2. Product Portfolio
- 14.3.10.3. SWOT Analysis
- 14.3.10.4. Financial Overview
- 14.3.10.5. Strategic Overview
- 14.3.1. Teva Pharmaceutical Industries Ltd.
